OMEROMEROS CORP
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$122M
- 27% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $71M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired11% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$174M | −$163M | −$165M | −$167M | −$123M | 26% |
| Net income | $194M | $47M | −$118M | −$157M | −$3M | 98% |
| Operating cash flow | −$110M | −$86M | $75M | −$149M | −$116M | 22% |
| Capex | $277K | $113K | $426K | $165K | $65K | 61% |
| Stock-based comp | $18M | $14M | $12M | $10M | $8M | 22% |
| Buybacks | $0 | $0 | $5M | $12M | $0 | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $419K · 2
- Net
- −$419K
Pay vs performance
No pay-versus-performance disclosure yet.